Equillium Inc
USUSDEquillium Inc (US:EQ) — Biotechnology: Pharmaceutical Preparations. Biržu skaits, kurās tiek tirgotas uzņēmuma akcijas: 2. Šajā lapā — cena un grafiks, dividendes, lielākie akcionāri un akciju skaita vēsture.
Par Uzņēmumu
- Tīmekļvietne
- equilliumbio.com
- Nozare
- Health Care · Biotechnology: Pharmaceutical Preparations
- Galvenā Mītne
- LA JOLLA, United States
- Izpilddirektors
- Bruce Steel
- Darbinieki
- 14
- Apgrozībā Esošās Akcijas
- 63.41 milj. uz 2026-08-07
- Brīvā Apgrozība
- 36.97 milj.
- Tirgus Kapitalizācija
- 89.41 milj. USD
- Iekšējās Personas
- 16%
- Institucionālie Investori
- 65.76%
- Nozare (SIC)
- Pharmaceutical Preparations
- P/E
- zaudējumi
- FCF
- −20.1 milj. USD
- Parāds
- 7.64 milj. USDneto nauda
- Peļņa un FCF — par 12 mēnešiem līdz 30.06.2026 (uzņēmuma jaunākais ziņojums).
Apraksts
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Ziņas Šonedēļ
Preses relīzes no uzņēmuma investoru mājaslapas, kas tiek atjauninātas katru dienu. Saites ved uz uzņēmuma mājaslapu. Virsraksti ir oriģinālvalodā, kā uzņēmuma mājaslapā.
Lielākie Akcionāri
| Turētājs | Daļa | Akcijas | Pārskata Datums |
|---|---|---|---|
| Jupiter Topco LLC | 10.24% | 6.49 milj. | 2026-06-30 |
| Decheng Capital LLC | 7.01% | 4.45 milj. | 2026-06-30 |
| Affinity Asset Advisors,… | 6.47% | 4.1 milj. | 2026-06-30 |
| Adar1 Capital Management… | 5.93% | 3.76 milj. | 2026-06-30 |
| Aberdeen Group plc | 5.73% | 3.63 milj. | 2026-06-30 |
| abrdn Life Sciences Inve… | 5.73% | 3.63 milj. | 2026-06-30 |
| Woodline Partners LP | 5.52% | 3.5 milj. | 2026-06-30 |
| RA Capital Management, L… | 4.88% | 3.1 milj. | 2026-06-30 |
| Stempoint Capital LP | 3.18% | 2.02 milj. | 2026-06-30 |
| Vanguard Capital Managem… | 2.87% | 1.82 milj. | 2026-06-30 |
| Eversept Partners, LP | 2.4% | 1.52 milj. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.21% | 1.4 milj. | 2026-06-30 |
| CONNELLY STEPHEN (Presid… | ≈1.2% | 762 025 | 2026-06-05 |
| VANGUARD INDEX FUNDS-Van… | 0.54% | 344 489 | 2026-06-30 |
| Fidelity Concord Street… | 0.26% | 162 851 | 2026-07-31 |
| iShares Trust-iShares Mi… | 0.24% | 153 076 | 2026-08-31 |
| American Century ETF Tru… | 0.12% | 75 411 | 2026-08-31 |
| ZEDELMAYER CHRISTINE (Ch… | ≈0.1% | 62 586 | 2026-06-05 |
| Fidelity Concord Street… | 0.09% | 54 677 | 2026-07-31 |
| Fidelity Concord Street… | 0.07% | 47 465 | 2026-07-31 |
| Invesco Exch-Trd Fd. TRT… | 0.06% | 38 516 | 2026-08-31 |
| Fidelity Concord Street… | 0.06% | 36 683 | 2026-07-31 |
| TOM PENNY (Officer) | — | 0 | 2026-05-28 |
| KEYES JASON A (Chief Fin… | — | — | 2025-01-23 |
